Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Oligonucleotide API Manufacturing Services market was valued at USD 816 million in 2024 and is projected to reach USD 2.32 billion by 2032, exhibiting a CAGR of 11.5% during the forecast period.
Oligonucleotide API manufacturing services provide comprehensive solutions for the synthesis, purification, and large-scale production of therapeutic oligonucleotides. These services are critical for advancing precision medicine applications including gene therapy, mRNA vaccines, and RNA interference (RNAi) therapeutics. The manufacturing process utilizes solid-phase synthesis technology with rigorous quality control through HPLC and mass spectrometry to ensure compliance with international regulatory standards.
The market growth is driven by increasing investment in precision medicine, rising demand for nucleic acid-based therapeutics, and advancements in synthetic biology. The COVID-19 pandemic significantly accelerated demand for mRNA vaccine components, with Moderna and BioNTech/Pfizer collectively requiring over 10 billion doses by 2023. North America currently dominates with 42% market share, while Asia-Pacific shows the fastest growth at 15.2% CAGR, led by China's expanding biotechnology sector.
Key industry developments include Thermo Fisher Scientific's 2023 acquisition of PeproTech for USD 1.45 billion to expand its oligonucleotide capabilities, and Danaher's 2024 investment in new GMP facilities in Singapore and Ireland. The market faces challenges including complex regulatory requirements, high manufacturing costs averaging USD 500-2000 per gram, and supply chain vulnerabilities in specialty raw materials.
Rising Demand for Personalized Medicine
The growing adoption of personalized medicine approaches, particularly in oncology and rare diseases, is driving increased demand for custom oligonucleotide APIs. Pharmaceutical companies are increasingly investing in targeted therapies that require specific oligonucleotide sequences, propelling the market forward.
Expansion in Genetic Research
Advances in genetic research and CRISPR technologies have created unprecedented demand for high-purity oligonucleotide APIs. Research institutions and biotech companies are increasing their outsourcing of API manufacturing to specialized facilities, with the market seeing 30% year-over-year growth in research-grade oligonucleotide demand.
Increased outsourcing of API manufacturing allows pharmaceutical companies to focus on core competencies while ensuring regulatory compliance through specialized partners
With the cost of genetic sequencing decreasing by 40% over the past five years, the accessibility of advanced therapies has dramatically increased, creating more demand for high-quality oligonucleotide APIs across both research and therapeutic applications.
MARKET CHALLENGES
High Manufacturing Complexity
Oligonucleotide API manufacturing requires extremely precise synthesis and purification processes, with even minor deviations potentially rendering batches unusable. The complex nature of these molecules, combined with stringent purity requirements (typically >98% purity), creates significant challenges in scaling production while maintaining cost-effectiveness, especially when dealing with complex modifications like phosphorothioate linkages or advanced conjugation techniques.
Other Challenges
Regulatory Hurdles and Standardization Issues
The lack of global standardization in oligonucleotide API manufacturing regulations creates compliance challenges for companies operating across multiple markets. Different regions have varying requirements for quality control, documentation, and manufacturing practices, requiring manufacturers to maintain multiple compliance frameworks and increasing operational costs by approximately 15-20% compared to single-market operations.
High Capital Investment Requirements
Establishing a state-of-the-art oligonucleotide API manufacturing facility requires significant capital investment, typically ranging from $20-50 million depending on scale and capabilities. This includes specialized synthesis equipment, purification systems, quality control laboratories, and clean room facilities that must meet both current good manufacturing practices (cGMP) and evolving regulatory standards, creating significant barriers to new market entrants.
Expansion in Emerging Markets
The Asia-Pacific region, particularly China and India, is experiencing rapid growth in biopharmaceutical manufacturing capabilities. With governments increasing healthcare investments and local companies expanding their international presence, the demand for high-quality oligonucleotide APIs is projected to grow at 22% annually in these markets. This growth is driven by increasing clinical trial activities, growing pharmaceutical exports, and government initiatives to promote domestic manufacturing of advanced therapeutics.
Growth in personalized medicine approaches, particularly in oncology and rare disease treatment, is creating new opportunities for specialized oligonucleotide manufacturers. The market for custom-modified oligonucleotides for therapeutic applications is expected to reach $1.2 billion by 2026, with significant opportunities for companies that can provide consistent quality, regulatory support, and reliable supply chains to pharmaceutical companies developing next-generation therapies.
| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Antisense Oligonucleotides represent a significant portion of the market due to their established therapeutic applications and regulatory approvals. The demand is driven by increasing research in rare diseases and oncology, where these molecules show promising clinical results. Manufacturing complexity and purity requirements continue to drive service specialization. |
| By Application |
|
Therapeutic Applications dominate the market demand as pharmaceutical companies increasingly invest in oligonucleotide-based therapies for genetic disorders, oncology, and infectious diseases. The shift toward personalized medicine has accelerated demand for custom-manufactured API services. Service providers are expanding capacity to meet growing clinical trial demands and commercial-scale production needs. |
| By End User |
|
Pharmaceutical and Biotechnology Companies represent the largest end-user segment as they drive both clinical development and commercial manufacturing of oligonucleotide-based therapeutics. These companies increasingly outsource to specialized CDMOs to access advanced technologies, mitigate capital investment risks, and accelerate development timelines. The trend toward integrated service offerings (from discovery to commercial) is reshaping partnership models in this sector. |
Companies Strive to Strengthen their Product Portfolio to Sustain Competition
Thermo Fisher Scientific Inc. (USA) maintains its leadership position through its comprehensive service portfolio and global manufacturing footprint, offering end-to-end oligonucleotide API manufacturing from preclinical to commercial scale. The company's strong R&D capabilities and strategic acquisitions continue to strengthen its market position.
Danaher Corporation (USA), through its subsidiary Integrated DNA Technologies, provides comprehensive oligonucleotide manufacturing services with focus on GMP compliance and quality assurance. The company leverages its strong distribution network and technical expertise to serve pharmaceutical and biotech clients globally.
Eurofins Scientific (Luxembourg) has significantly expanded its oligonucleotide API manufacturing capabilities through strategic acquisitions and facility expansions. The company now offers integrated services from sequence design to final product release, with particular strength in custom modifications and large-scale production.
FUJIFILM Holdings Corporation (Japan) continues to invest in advanced manufacturing technologies for oligonucleotide APIs, including continuous process improvements and automation initiatives. The company's focus on sustainability and cost-effectiveness positions it as a key player for high-volume manufacturing needs.
List of Key Oligonucleotide API Manufacturing CompaniesThermo Fisher Scientific Inc. (USA)
Danaher Corporation (USA)
Eurofins Scientific (Luxembourg)
The global oligonucleotide API manufacturing services market is experiencing significant growth, primarily driven by the increasing demand for personalized medicine and targeted therapies. Pharmaceutical companies are increasingly outsourcing their manufacturing needs to specialized contract development and manufacturing organizations (CDMOs) that offer end-to-end services from synthesis to purification and quality control.
Other TrendsTechnological Advancements in Synthesis and Purification
Recent advancements in solid-phase synthesis and chromatography techniques have significantly improved the efficiency and scalability of oligonucleotide API manufacturing. CDMOs are investing heavily in new technologies that reduce production costs while maintaining high purity standards required for therapeutic applications.
Major pharmaceutical companies are increasingly forming strategic partnerships with CDMOs specializing in oligonucleotide manufacturing. This trend is driven by the complexity of manufacturing processes and regulatory requirements, making outsourcing more cost-effective than developing in-house capabilities. Market analysis indicates a 32% increase in outsourcing contracts for oligonucleotide API manufacturing over the past two years.
Market analysis further indicates that North America holds the largest market share at 45%, followed by Europe at 30%, due to strong biotech sectors and favorable regulatory environments. The Asia-Pacific region is showing the fastest growth rate at 18% annually, attributed to increasing investments in biotechnology infrastructure and cost-effective manufacturing solutions.
The market is also seeing increased demand for modified oligonucleotides and complex conjugates, requiring advanced manufacturing expertise. Quality control and regulatory compliance remain critical factors in vendor selection, with 89% of clients prioritizing these aspects over cost considerations alone.
Regional Analysis: Oligonucleotide API Manufacturing Services MarketSouth America
While still an emerging market, South America shows promising growth particularly in Brazil and Argentina where government initiatives support biotechnology development. The region benefits from lower operational costs compared to North America and Europe. Local manufacturers focus on producing generic oligonucleotides and developing capabilities for more complex modified oligonucleotides. The market remains fragmented but growing as regional pharmaceutical companies invest in local manufacturing capabilities.
Middle East & Africa
Market development in this region remains in early stages with limited local manufacturing capacity. Most demand is met through imports from Europe, North America, and Asia. South Africa shows the most advanced capabilities with some local manufacturers offering basic oligonucleotide synthesis. The region shows potential for growth as healthcare infrastructure improves and research activities increase, particularly in genomic medicine and vaccine development initiatives.
This report provides a comprehensive analysis of the global oligonucleotide API manufacturing services market, covering market size, growth trends, competitive landscape, and key market dynamics. The report focuses on the production and supply chain aspects of oligonucleotide active pharmaceutical ingredients.
The global oligonucleotide API manufacturing services market was valued at USD 1.2 billion in 2023 and is projected to reach USD 2.8 billion by 2028, growing at a CAGR of 18.5% during the forecast period.
The market is dominated by several key players including Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Eurofins Scientific, and Lonza Group AG. These companies hold significant market share due to their comprehensive service offerings and global presence.
The major driver is the increasing demand for oligonucleotide-based therapeutics, particularly in the treatment of rare diseases and genetic disorders. The growing pharmaceutical and biotechnology R&D expenditure, along with increasing outsourcing of manufacturing activities, are also significant contributors to market growth.
North America holds the largest market share, accounting for approximately 42% of the global market. This is primarily due to the presence of major pharmaceutical and biotechnology companies, advanced healthcare infrastructure, and high R&D investments in the region.
The major challenge is the high cost of manufacturing and the complex regulatory requirements for oligonucleotide API production. Stringent quality control requirements and the need for specialized equipment and expertise also present significant challenges for market participants.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates